Clinical Trials
17 trialsNCT06469944 2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06312176 2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06966700 2026-05-22
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05152147 2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT04895358 2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04882241 2026-03-06
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03675737 2026-02-27
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03615326 2025-12-11
MK-3475-811
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04428151 2025-12-04
LEAP-009
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02611960 2023-07-13
Keynote-122
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02494583 2023-04-13
MK-3475-062
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02335411 2022-08-08
KEYNOTE-059
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04859582 2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT02555657 2021-12-10
KEYNOTE-119
Merck Sharp & Dohme LLC
Phase 3 Completed